Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

598 - Analysis of the overall survival and main surrogates used for FDA approvals in solid and hematological malignancies.

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Clinical Research

Tumour Site

Presenters

Maria Kleniewska-Wieczor

Citation

Annals of Oncology (2019) 30 (suppl_5): v159-v193. 10.1093/annonc/mdz244

Authors

M. Kleniewska-Wieczor1, L. Mendoza2

Author affiliations

  • 1 Medical And Scientific Services, Iqvia RDS Poland sp. z o.o., 02-672 - Warsaw/PL
  • 2 Medical And Scientific Services, IQVIA, 186 00 - Prague/CZ

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 598

Background

U.S. Food and Drug Administration (FDA) approves drugs based on overall survival (OS) in oncology trials in order to speed up access of novel drugs to the market.

Methods

We examined all adult anticancer drugs approved by the FDA from Jan’2006 to Jan’2019. Data regarding the approval type (regular or accelerated), cancer type, treatment indication, and basis for approval were extracted from the FDA website and any relevant publications. The basis for approval was categorized into the response rate (RR), progression-free survival (PFS), and overall survival (OS) endpoints and their analysis. Approvals for pediatric cancers, biosimilars, and cancers limited to genetic syndromes were not included in this study.

Results

A total of 258 FDA approvals were analyzed, of which 57 (22.09%) were approved for first-line therapy and 201 (77.91%) for subsequent lines. Sixty-six (25.58%) were approved based on the OS endpoint, 23 (8.91%) in the first line and 43 (16.67%) in the subsequent lines. One hundred ninety-two (74.42%) drugs were granted approval (regular and accelerated) based on surrogate endpoints: 104 (40.31%) of them for RR and 87 (33,72%) for PFS. Thirteen (5.04%) and 91 (35.27%) were approved for RR, and 20 (7.75%) and 67 (25.97%) were approved for PFS in the first and subsequent lines, respectively (Table). Table Out of the total 258 FDA approvals, 66 (25.58%) were accelerated and 192 (74.42%) regular. Ten (3.88%) and 56 (21.71%) obtained accelerated approval in the first and subsequent lines, respectively. Forty-seven (18.22%) and 145 (56.20%) were granted regular approval in the first and subsequent lines, respectively.Table:

486P

Lines of treatment# of approvals for RR (%)# of approvals for PFS (%)# of approvals for OS (%)Total # of approvals (%)
First line13 (5.04)20 (7.75)23 (8.91)57 (22.09)
Subsequent lines91 (35.27)67 (25.97)43 (16.17)201 (77.91)
Total104 (40.31)87 (33.72)66 (25.58)258 (100)

Conclusions

RR and PFS were the most frequently approved surrogate endpoints, most often for use in later lines of therapy. The accelerated approvals based on surrogate endpoints in later lines of therapy represent a topic of current debate.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.